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Abstract 40 
Bovine viral diarrhea virus (BVDV) has been detected in peripheral blood 41 
mononuclear cells (PBMCs) of immunocompetent animals, not being clear whether the 42 
development of a specific humoral immune response can prevent BVDV infection. The aim 43 
of this study was to evaluate the ability of non-cytopathic BVDV to replicate and produce 44 
infectious virus in PBMCs from calves pre-infected with BVDV and to elucidate the 45 
immunomodulatory effect of BVDV on these cells in an in vitro model. Quantification of 46 
virus was by quantitative PCR, while its replicative capacity and shedding into the 47 
extracellular environment was evaluated by viral titration. Apoptosis was assessed by flow 48 
cytometry analysis of annexin V and propidium iodide, and by expression of caspase-3/7. 49 
Flow cytometry was used to analyze the expression of CD14/CD11b/CD80, CD4/CD8/CD25, 50 
MHC-I/MHC-II and B-B2 markers. Our results showed that PBMCs from cattle naturally 51 
infected with BVDV were more susceptible to in vitro BVDV infection and showed a more 52 
severe apoptosis response than those from naïve animals. Non-cytopathic BVDV in vitro 53 
infection also resulted in a lack of effect in the expression of antigen presentation surface 54 
markers. All these findings could be related to the immunosuppressive capacity of BVDV 55 
and the susceptibility of cattle to this infection.  56 
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1. Introduction 63 
Bovine viral diarrhea virus (BVDV) is responsible for acute and persistent infection in 64 
cattle, as well as for establishing immunosuppressive mechanisms that favor secondary 65 
infections [1]. BVDV can lead to acute infection in susceptible immunocompetent cattle, 66 
persistent infection, or chronic infection in immune-privileged sites [2]. The most important 67 
consequences for herds occur when a non-cytopathic (ncp) BVDV strain infects a susceptible 68 
cow early in gestation; the fetus becomes immunotolerant to this infecting viral strain and 69 
remains persistently infected (PI), shedding the virus throughout its lifetime and serving as a 70 
reservoir of infection for naïve animals [3].  71 
The immunosuppressive effect of BVDV is attributed to its ability to infect T and B 72 
lymphocytes and monocytes, the main components in percentage terms of peripheral blood 73 
mononuclear cell (PBMC) populations [4,5]. Infection of PBMCs disrupts the normal 74 
mechanisms of immune stimulation, leading to immune evasion and chronic infection [6]. In 75 
general, ncp BVDV strains induce large decreases in white blood cell counts [7,8], as well as 76 
the expression of major histocompatibility complex (MHC) type II and CD80/86 in antigen-77 
presenting cells (APCs) [9,10,11]. Furthermore, T cell proliferation response in ncp BVDV 78 
infections is slower and less prolonged than in cytopathic (cp) BVDV [12,13,14].  79 
There are also many studies measuring antibody neutralization and cross-80 
neutralization of BVDV strains to prevent disease after vaccination [15]. An in vitro study 81 
demonstrated that lymphocytes in cattle that had been vaccinated against BVDV were less 82 
efficiently infected than in naïve animals [16]. However, BVDV antigens have been detected 83 
in PBMCs in seropositive animals with the presence of neutralizing antibodies [17,18] and an 84 
in vitro infection model demonstrated that PBMCs from immune animals were permissive to 85 
BVDV re-infection by homologous or heterologous strains [19].  86 
 4 
A variety of mechanisms enabling evasion of the host immune response has been 87 
proposed to explain the immunosuppressive effect of BVDV in naïve animals, although so far 88 
no experimental studies have been performed to determine which specific mechanisms 89 
developed by BVDV predispose to re-infection in seropositive animals. The aims of this 90 
study were to evaluate the ability of ncp BVDV to replicate and produce infectious virus in 91 
PBMCs in calves pre-infected with BVDV and try to elucidate the immunomodulatory effect 92 
of BVDV on these cells that favors possible BVDV re-infection.  93 
 94 
2. Materials and methods 95 
2.1. Animals 96 
Two dairy herds were selected based on the serological and virological BVDV results 97 
among herds participating in an infectious disease control program [20].  98 
Sera and PBMCs were collected from eight heifers (10-12 months old; purebred 99 
Holstein–Friesian or mixed with other breeds) divided into two groups: i) the naïve group, 100 
four BVDV-seronegative animals from a herd negative for BVDV antibodies at two 101 
serological surveys performed at least 6 months apart; ii) the BVDV pre-infected group, 102 
comprising four BVDV-seropositive animals from a herd with ongoing infection caused by a 103 
PI animal with a BVDV-1 strain slaughtered 2 months earlier. The experimental protocol of 104 
animal handling was approved by the Italian Ministry of Health (protocol number 105 
2006070977-003). 106 
BVDV viremic status was tested by RT-PCR [21]. BVDV antibody status in serum 107 
was evaluated by competitive ELISA (Ingezim BVD Compac, Ingenasa) and virus 108 
neutralization (VN) tests against cp BVDV-1a (NADL strain, ATCC® VR-534TM). For the 109 
VN, a Madin Darby Bovine Kidney cell line (MDBK, ATCC® CCL-22TM) was used, 110 
maintained in complete culture medium [MEM supplemented with 10% of fetal calf serum 111 
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(FCS), L-glutamine 2mM, antibiotics and antifungal agents] (Euroclone). The VN titer for 112 
each serum was the highest dilution at which the virus was neutralized in 50% of the wells 113 
[22]. Animals were regarded as seronegative when no neutralization was observed at the 114 
lowest dilution (1:4). 115 
At the time of the study, naïve animals were confirmed to be free from both BVDV 116 
antigens and antibodies, while animals pre-infected with BVDV through exposure to the PI 117 
calf were confirmed to be BVDV antigen-free and VN antibody titers to BVDV-1 were >128. 118 
The leukocyte profile was analyzed with the Sysmex XT-2000iV hematology analyzer, using 119 
specific settings for bovine blood (Sysmex Corporation, Kobe, Japan). Total leukocyte and 120 
platelet counts were within the normal range for bovine (Table 1) [23]. 121 
 122 
Table 1. Mean ± standard deviation (n=4) of total leukocyte and platelet counts from the 123 
animals used in this study, and normal reference values. 124 
 125 
(n x 103/μl) BVDV pre-infected group Naïve group Normal values1 
Lymphocytes 5.31 3.86 4.5 (2.5-7.5) 
Monocytes 0.9 1.05 0.4 (0.02-0.8) 
Neutrophils 1.98 1.55 2 (0.6-4) 
Eosinophils 0.11 0.43 0.7 (0-2.4) 
Basophils 0.10 0.12 0.05 (0-0.2) 
Total leukocytes 8.40 7.00 8 (4-12) 
Platelets 351 197.50 500 (100-800) 
  1 Normal blood values for cattle (Schalm’s veterinary hematology. 4th ed. Philadelphia: Lea & 126 
 Febiger, 1986) 127 
 128 
 129 
2.2. Virus  130 
 Ncp BVDV-1 was used for the in vitro infection, since it is the most prevalent 131 
genotype of BVDV [24]. Experiments were performed with the ncp BVDV-1 7443 strain 132 
(courtesy of the Institut für Virologie, Hanover, Germany), which had been used for in vivo 133 
infections [8,25,26].  134 
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 The titer of the virus stock was determined by immunoperoxidase monolayer assay 135 
(IPMA) in MDBK cells, as described by Lucchini et al. [19]. Final ncp BVDV-1 strain 7443 136 
stocks of 104.6 tissue culture infectious dose 50%/μl (TCID50/μl) were used to infect PBMCs. 137 
PBMCs were incubated at 37ºC for 2 hours with BVDV at a multiplicity of infection (m.o.i.) 138 
of 1, as laid down previously in other studies [4,19,27], showing that PBMCs were 139 
efficiently infected with higher viral loads compared to 0.1 m.o.i. 140 
 141 
2.3 Cell separation, culture and infection of PBMCs 142 
Blood collection was by jugular venipuncture using sterile bags containing CPDA-1, 143 
centrifuged at 1,200 x g for 30 min at room temperature (RT) and the buffy coat separated 144 
and resuspended 1:2 in PBS. The buffy coat was diluted 2:1 and layered onto the Histopaque-145 
1077 (Sigma-Aldrich), then centrifuged at 1,200 x g for 30 min at RT before collection of the 146 
ring of PBMCs at the interface. Live cells were counted by the trypan blue dye exclusion test 147 
and resuspended in RPMI-1640 medium at 1x106 cells/ml. Cells from each animal were 148 
separated into mock-infected control and BVDV-infected with ncp BVDV-1 at a m.o.i. of 1 149 
for 2 hours at 37ºC. The inoculum was removed by washing the cells in RPMI-1640 medium 150 
to eliminate extracellular virus. Cells were resuspended in leukocyte culture medium [RPMI-151 
1640, 1% L-glutamine, 25 mM Hepes and 10% FCS] (Euroclone) and incubated in 5% CO2 152 
at 37ºC for 18, 24 and 48 hours post-inoculation (hpi). 153 
PBMCs were harvested at each time point, removing adherent cells after incubating 154 
for 10 min with cell-dissociation solution (Sigma-Aldrich). Supernatants were separated from 155 
cells by centrifugation at 400 x g for 10 min. 156 
  157 
2.4. Virus assays in PBMCs infected with BVDV  158 
2.4.1. Virus quantification at 18, 24 and 48 hpi 159 
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RNA extraction from cell culture supernatants (extracellular BVDV) and freeze-160 
thawed PBMCs at -80ºC (intracellular BVDV) was performed using the QIAamp Viral RNA 161 
Mini Kit (QIAgen). The total RNA concentration in each sample was quantified with a 162 
NanoDrop ND-1000 UV–vis spectrophotometer (NanoDrop Technologies Inc.) and its purity 163 
assessed using the A260/A280 ratio. The RNA (1μg) was retrotranscribed using the iScript 164 
cDNA Synthesis kit (Bio-Rad Laboratories). 165 
External standards were constructed to enable quantification of PCR products from 166 
ncp BVDV-1 strain 7443 [28], and consisted of plasmids containing inserts of the amplified 167 
BVDV gene sequences ranging from 1 to 108 copies of virus cDNA/µl. 168 
Quantitative reactions were performed in 12µl of EvaGreen Supermix (Bio-Rad 169 
Laboratories) with 500 nM BVDV primers and 1µl cDNA, using the Eco Real-Time PCR 170 
thermal cycler system (Illumina Inc.). Each sample was tested in duplicate with the thermal 171 
profile set at 50 ºC for 2 min, 95 ºC for 7 min, followed by 40 cycles at 95 ºC for 10 s and at 172 
60ºC for 30s. Reverse transcription controls were performed by omitting the reverse 173 
transcription reaction, and template controls by adding nuclease-free water. Copy numbers of 174 
BVDV RNA/µg were calculated by reference to the standard curves. Results were expressed 175 
in absolute copy numbers. The detection limit was 10 copies for BVDV plasmids. 176 
PCR controls included genomic RNA isolated from BVDV-negative PBMCs and 177 
MDBK cells, as well as negative reagents, such as water.  178 
 179 
2.4.2. Virus titration at 18, 24 and 48 hpi 180 
To evaluate the in vitro replication rate of BVDV in PBMCs, extracellular virus titers 181 
were determined by microtiter assay on 96-well plates. Briefly, quadruplicate 10-fold serial 182 
dilutions of the tested supernatants were made in MEM with a MDBK cell suspension of 1.5 183 
x 104 cells/ml. The plate was incubated for 4 days at 37ºC with 5% CO2, and an IPMA was 184 
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performed to detect the ncp BVDV strain, using monoclonal antibody 20.10.06 with cross-185 
reactivity against the NS2/3 protein of BVDV (courtesy of Dr. E. Dubovi, Cornell 186 
University). Viral titers were calculated using the Reed-Muench method [22] and expressed 187 
as log10 TCID50/μl. 188 
Intracellular viral titers could not be calculated due to insufficient sample volume. 189 
 190 
2.5. Flow cytometry  191 
PBMCs from both groups were harvested at 18, 24 and 48 hpi, divided into aliquots of 192 
2x105 cells/100μl and incubated for 30 min at RT with optimally diluted mouse monoclonal 193 
antibodies (Table 2), including isotype-matched controls. For indirect labeling of B cells, 194 
cells were incubated with FITC-conjugated goat anti-mouse secondary antibody. After two 195 
washes, cells were fixed with 1% formaldehyde (CellFix 10x; Becton, Dickinson and 196 
Company) in PBS and kept in the dark at 4ºC until analysis. Cells (1x104 events) were 197 
analyzed on the FACSCalibur cytometry system (Becton, Dickinson and Company) and 198 
immunofluorescence staining was analyzed using Flowing Software (version 2.5.0). Results 199 
were expressed as the percentage or the mean fluorescence intensity (MFI geometric mean of 200 
the channel number) of the surface molecules stained on the gated cells. Three-, two- or 201 
single-color staining for leukocyte differentiation antigens was performed, as follows: 202 
CD14/CD11b/CD80, CD4/CD8/CD25, MHC-I/MHC-II and B-B2. Gate strategy of the flow 203 
cytometry analysis of PBMCs is represented in the Supplementary Figure 1. 204 
 205 
 206 
 207 
 208 
 209 
 210 
 211 
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Table 2. List of antibodies used for flow cytometry  212 
*Clone-Fluorochrome Specificity  Isotype Source 
TÜK4-AlexaFluor 647 anti-human CD14 IgG2a Serotec 
CC126-FITC anti-bovine CD11b IgG2b Serotec 
ILA159-RPE anti-bovine CD80 IgG1 Serotec 
CC8-FITC anti-bovine CD4 IgG2a Serotec 
CC63-AlexaFluor 647 anti-bovine CD8 IgG2a Serotec 
ILA111-RPE anti-bovine CD25 IgG1 Serotec 
ILA88-FITC anti-bovine MHC-I IgG2a Serotec 
CC108-RPE anti-bovine MHC-II IgG1 Serotec 
CC219-FITC anti-bovine CD28 IgG1 Serotec 
BAQ44A 
(unconjugated) 
anti-bovine B cells (B-
B2) 
IgM VMRD 
Secondary Ab-FITC goat anti-mouse IgM (Secondary Ab) Sigma-
Aldrich 
 *All primary antibodies are monoclonal mouse antibodies.   213 
 214 
2.6. Apoptosis assay 215 
2.6.1. Measurement of PBMCs apoptosis by annexin V-FITC binding assay 216 
Ca2+-dependent binding of annexin V (AV)-FITC to phosphatidylserine was used to 217 
measure apoptosis in PBMCs. Dual staining with AV and propidium iodide (PrI) was used to 218 
discriminate between apoptotic and necrotic cells (MBL MEBCYTO Apoptosis kit). PBMCs 219 
were double-stained with AV and PrI diluted in binding buffer for 15 min at RT in the dark 220 
after 18, 24 and 48 hpi. The AV–/PrI– population represented live cells; the AV+/ PrI– 221 
population represented early apoptotic cells; the AV+/PrI+ population represented late-stage 222 
apoptotic and necrotic cells. PBMCs were analyzed on a FACSCalibur cytometer (Becton 223 
Dickinson Immunocytometry Systems) with excitation at 488 nm. A minimum of 2,000 224 
events per sample were analyzed. 225 
 226 
2.6.2. Measurement of apoptosis in PBMCs by caspase-3/7 227 
Caspase-3 and -7 activity in PBMCs was detected at 18, 24 and 48 hpi using the Apo-228 
ONETM detection assay (Promega Corporation), following the manufacturer's instructions. 229 
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Fluorescence intensity was measured using a fluorescence plate reader Fluoroscan Ascent 230 
(Thermo Electron Corporation) and was expressed as RFU (Relative Fluorescence Units). 231 
  232 
2.7. Statistical analysis 233 
Statistical analysis was carried out using GraphPad Prism version 6.0. The non-234 
parametric Mann–Whitney U test was used to analyze significant differences (P<0.05) 235 
between naïve and BVDV-pre-infected groups at the same time point (*), as well as between 236 
the in vitro BVDV-infected and (mock) control PBMCs (a: naïve animals; b: BVDV pre-237 
infected animals).  238 
 239 
3. Results  240 
3.1. BVDV replication in PBMCs 241 
BVDV RNA was not detected in the PBMCs or culture supernatants from the mock-242 
inoculated samples of the two animal groups. There was scant detection of intracellular 243 
BVDV in PBMCs in both animal groups during this experiment, with slightly higher rates 244 
observed only at 48 hpi. Nonetheless, at 18 and 24 hpi, the quantity of BVDV RNA in the 245 
culture supernatants of PBMCs from pre-infected animals was significantly greater than in 246 
PBMCs from naïve animals (P0.0001) (Figure 1).  247 
The ability of BVDV to shed infectious virus in PBMCs to the extracellular 248 
environment was evaluated by measuring viral titers in the culture supernatants. 249 
Immunolabeling did not detect the presence of BVDV in MDBK cells treated with culture 250 
supernatants from mock-infected PBMCs. Throughout the experiment, PBMCs culture 251 
supernatants from both naïve and pre-infected groups showed consistently low extracellular 252 
BVDV titers, with a significant difference (P<0.05) between groups at 48 hpi (Figure 2).  253 
 254 
 11 
3.2. Ability of BVDV to stimulate T-cell responses 255 
There was no observable evidence that BVDV had a statistically significant down-256 
regulatory effect on the expression of CD14+ or CD11b+, although there seemed to be a 257 
downregulated expression of co-stimulatory molecules (CD14+) CD80+ in the monocyte 258 
populations of animals pre-infected with BVDV compared with naïve animals (Figure 3).  259 
After BVDV infection, no statistically significant differences were found in the 260 
percentages of T lymphocytes (CD4+ or CD8+ subpopulations), B-lymphocytes or in the 261 
expression of the CD25 activation marker in the PBMCs of the two animal groups, or in the 262 
same group over the whole study period (Figure 4). 263 
No significant changes were observed for the MFI of MHC-I and MHC-II (Figure 4), 264 
or (CD14+) CD11b+, (CD14+) CD80+ and (CD4+) CD25+ (data not shown) in both groups.  265 
 266 
3.3. Ability of BVDV to induce cell death 267 
PBMCs from naïve and pre-infected animals displayed decreased cell viability (mean 268 
percentage of live cells) after 18 hpi, and an apoptotic effect was observed in up to 60% of 269 
PBMCs primary cultures at 48 hpi (data not shown). The percentage of early apoptotic cells 270 
was higher in naïve animals than in those pre-infected with BVDV. Nevertheless, the 271 
enzymatic activity of caspase-3/7, the executioner enzymes in the final pathway of apoptosis, 272 
was significantly higher (P<0.05) in BVDV- pre-infected animals at 48 hpi (Figure 5). 273 
 274 
4. Discussion 275 
PBMCs represent the main target for replication of BVDV in in vitro systems [4,5]. 276 
Our results showed that PBMCs from both naïve animals and those pre-infected with BVDV 277 
were efficiently infected in vitro with BVDV in the conditions tested. PBMCs from BVDV 278 
pre-infected animals were more susceptible to BVDV infection in vitro and presented a 279 
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higher ability to release infectious BVDV into the extracellular environment. This could 280 
represent a survival strategy of ncp BVDV strains, enabling the BVDV to be more readily 281 
disseminated and to persist in the host cell population [14]. However, our results did not 282 
agree with those reported by Lucchini et al. [19], who observed lower BVDV titers in 283 
PBMCs cultures from immunized animals than from naïve ones, although the immunized 284 
animals were incompletely protected against heterologous BVDV strains. These findings 285 
suggest the involvement of a cell-mediated immune response able to control the BVDV load, 286 
and also that re-infections should be considered for their potential impact on vaccination 287 
programs.  288 
Maintenance of the percentage of monocytes in naïve and BVDV-pre-infected groups 289 
was consistent with other in vitro studies showing that infection with a ncp strain did not kill 290 
purified monocytes [6] or monocyte-enriched cell cultures [29]. These similarities have also 291 
been observed in the absence of significant changes in CD11b expression in purified cell 292 
cultures after BVDV infection [6], thus reducing the possibility that expression of this marker 293 
may be partly responsible for impairment of the immune response associated with BVDV. 294 
Analyses of CD80/86 expression during BVDV infection and its possible effect on APC 295 
functions have shown variable results, ranging from downregulation of gene expression in 296 
vivo [9] and in vitro [10,11] to no effect on surface expression [6]. In our study, while not 297 
significant, downregulation of CD80 was observed on monocytes from both BVDV-infected 298 
groups, suggesting that a higher infectious dose or prolonged exposure might induce more 299 
obvious changes. No significant changes in MHC-II were observed after ncp BVDV 300 
infection, which coincides with some studies carried out on monocytes [6], but contrasts with 301 
other ones that reported an inhibitory effect on MHC class II expression by ncp BVDV 302 
[10,11].  303 
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The lack of change in the percentage of T lymphocytes after in vitro BVDV infection 304 
contrasts with the significant decreases observed in in vivo ncp BVDV infections [8,30]. The 305 
absence of changes in our study could indicate that T lymphocytes do not proliferate in 306 
response to antigen presentation of the virus, which might be explained by the unchanged 307 
percentage of (CD4+) CD25+ subpopulation cells of both animal groups [31]. In the BVDV-308 
seropositive calves, these results contrast with the CD25 upregulation observed in other trials 309 
following infection or vaccination [32,33]. 310 
 The reported effects on circulating B-lymphocytes during in vivo infections with 311 
BVDV vary from a decreased number to no change [9,30], possibly due to differences in 312 
viral strains. No changes in the percentage of B lymphocytes were observed in this study, 313 
which contrasts with the affection in circulating B-cells or in lymphoid follicles in in vivo 314 
BVDV infections with the same strain [8,26]. These studies showed that activation of the 315 
initiator caspase-8 seems to play a major role in lymphocyte apoptosis, suggesting that this 316 
could be caused by an indirect mechanism mediated by pro-apoptotic cytokines released by 317 
macrophages [25]. In our study, PBMCs from the pre-infected group presented significant 318 
caspase-3/7 activation and expression after in vitro infection, which translated into an 319 
irreversible process of programmed cell death [34]. This suggests a possible association 320 
between BVDV-pre-infection and the apoptotic mechanisms by which this virus is able to 321 
induce an immunosuppressed state in susceptible cattle in order to facilitate viral infection 322 
[5,25]. 323 
 324 
5. Conclusions 325 
Our results showed that PBMCs from naturally infected BVDV-immune cattle are 326 
susceptible to BVDV re-infection of even greater intensity than those from naïve animals. 327 
This, together with the more severe apoptotic effects in pre-infected animals and the lack of 328 
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effect in the expression of surface markers characteristic of antigen presentation could be 329 
related to the immunosuppressive effect of the ncp BVDV strain and the susceptibility of 330 
cattle to this infection. Further studies to clarify the role played by cytokines in BVDV-331 
induced apoptosis are necessary in order to gain a more complete understanding of the 332 
pathogenesis of this disease. 333 
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 487 
Figure 1. BVDV replication in PBMCs. Means (±SEM) of the absolute copy numbers of 488 
BVDV in lysated and freeze-thawed PBMCs, and in the supernatants from naïve and BVDV-489 
pre-infected animals (n=4). Significant differences (P<0.05) between naïve and BVDV-pre-490 
infected groups at the same time point (*) and between the in vitro BVDV-infected and 491 
control (mock) PBMCs (a: naïve animals; b: BVDV-pre-infected animals). 492 
493 
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 494 
Figure 2. Ability of BVDV in PBMCs to produce infectious virus in the extracellular 495 
environment. Means (±SEM) of the log10 TCID50/ml of infectious BVDV in the culture 496 
supernatants (n=4). Significant differences (P<0.05) between naïve and BVDV-pre-infected 497 
groups at the same time point (*), and between in vitro BVDV-infected and (mock) control 498 
PBMCs (a: naïve animals; b: BVDV pre-infected animals). 499 
500 
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 501 
Figure 3. Effect of BVDV on monocytes and cell surface markers expression. Means (±SEM) 502 
of the percentage of monocytes (CD14+) expressing CD11b or CD80 in BVDV-infected 503 
PBMCs from naïve and pre-infected field cattle (n=4). Significant differences (P<0.05) 504 
between naïve and BVDV-pre-infected groups at the same time point (*) and between the in 505 
vitro BVDV-infected and (mock) control PBMCs (a: naïve animals; b: BVDV-pre-infected 506 
animals). 507 
508 
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 509 
Figure 4. Effect of BVDV on lymphocytes and cell surface markers expression. Means 510 
(±SEM) of the percentages of lymphocytes (CD4+ or CD8+ subpopulations) and B- 511 
lymphocytes, as well as expression of different cell surface markers in BVDV-infected 512 
PBMCs from naïve and pre-infected field cattle (n=4). Significant differences (P<0.05) 513 
between naïve and BVDV- pre-infected groups at the same time point (*), and between the in 514 
vitro BVDV-infected and control (mock) PBMCs (a: naïve animals; b: BVDV pre-infected 515 
animals). 516 
517 
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 518 
Figure 5. BVDV activation of induced cell death. Means (±SEM) of the cell death 519 
percentages of BVDV-infected PBMCs from naïve and pre-infected field cattle using the 520 
annexin V-FITC binding assay, and caspase-3/7 activity by colorimetric assay (relative 521 
fluorescence expressed as RFU -Relative Fluorescence Units-) (n=4). Significant differences 522 
(P<0.05) between naïve and BVDV pre-infected groups at the same time point (*), and 523 
between the in vitro BVDV-infected and (mock) control PBMCs (a: naïve animals; b: BVDV 524 
pre-infected animals). 525 
 526 
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 528 
Supplementary Figure 1. Gate strategy of the flow cytometry analysis of PBMCs. A) 529 
Monocytes. FL1 (FITC-CD11b), FL4 (AlexaFluor647-CD14), FL2 (RPE-CD80). FL3 (No 530 
stain). B) T lymphocytes. FL1 (FITC-CD4), FL4 (AlexaFluor647-CD8), FL2 (RPE-CD25). 531 
FL3 (No stain). 532 
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